217 related articles for article (PubMed ID: 29739095)
21. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
[TBL] [Abstract][Full Text] [Related]
22. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.
Jia Z; Ding Y; Tian S; Niu J; Jiang J
PLoS One; 2012; 7(9):e45698. PubMed ID: 23029188
[TBL] [Abstract][Full Text] [Related]
23. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.
Ridruejo E; Solano A; Marciano S; Galdame O; Adrover R; Cocozzella D; Delettieres D; Martínez A; Gadano A; Mandó OG; Silva MO
Ann Hepatol; 2011; 10(4):452-7. PubMed ID: 21911885
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.
Riva E; Scagnolari C; Monteleone K; Selvaggi C; Picardi A; Mazzarelli C; Pizzigallo E; Vincenzi B; Carducci A; Antonaci S; Giannelli G; Antonelli G
J Viral Hepat; 2012 Sep; 19(9):650-3. PubMed ID: 22863269
[TBL] [Abstract][Full Text] [Related]
25. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
Domagalski K; Pawłowska M; Tretyn A; Halota W; Pilarczyk M; Smukalska E; Linkowska K; Grzybowski T
Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):745-54. PubMed ID: 23314745
[TBL] [Abstract][Full Text] [Related]
26. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466
[TBL] [Abstract][Full Text] [Related]
27. IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort.
Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Vincze A; Szereday L; Kisfali P; Melegh B
BMC Res Notes; 2014 Jan; 7():12. PubMed ID: 24398031
[TBL] [Abstract][Full Text] [Related]
28. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
[TBL] [Abstract][Full Text] [Related]
29. Association of Interleukin 28B Polymorphism with Clearance of Hepatitis C Virus: A Mini Review.
Shaheen M; Afzal S; Khubaib B; Amin I; Shahid M; Idrees M
Crit Rev Eukaryot Gene Expr; 2020; 30(3):223-229. PubMed ID: 32749108
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.
Shi KQ; Liu WY; Lin XF; Fan YC; Chen YP; Zheng MH
Gene; 2012 Oct; 507(1):27-35. PubMed ID: 22842190
[TBL] [Abstract][Full Text] [Related]
31. IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.
Martínez-Gómez LE; Chávez-Tapia NC; Burguete-García AI; Aguilar-Olivos N; Madrid-Marina V; Román-Bahena M; Orbe-Orihuela C; Misael U; Méndez-Sánchez N
Ann Hepatol; 2012; 11(6):876-81. PubMed ID: 23109451
[TBL] [Abstract][Full Text] [Related]
32. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.
Suppiah V; Gaudieri S; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Hellard M; Riordan S; Matthews G; Sheridan D; Nattermann J; Smedile A; Müller T; Hammond E; Dunn D; Negro F; Bochud PY; Mallal S; Ahlenstiel G; Stewart GJ; George J; Booth DR;
PLoS Med; 2011 Sep; 8(9):e1001092. PubMed ID: 21931540
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C.
Mah YH; Liu CH; Chen CL; Tseng TC; Liu CJ; Chen PJ; Chen DS; Kao JH
J Formos Med Assoc; 2016 Nov; 115(11):953-960. PubMed ID: 27751759
[TBL] [Abstract][Full Text] [Related]
35. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
[TBL] [Abstract][Full Text] [Related]
36. Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.
Keshvari M; Alavian SM; Behnava B; Pouryasin A; Craig JC; Sharafi H
J Clin Lab Anal; 2017 Jul; 31(4):. PubMed ID: 27735085
[TBL] [Abstract][Full Text] [Related]
37. Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay.
Li W; Zeng Y; Wang J; Zhou B; Zhang J; Zhang H; Li J; Wu Y; Hamoudi R; Zhou Y
Antiviral Res; 2012 Apr; 94(1):54-6. PubMed ID: 22387386
[TBL] [Abstract][Full Text] [Related]
38. Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent.
Ranjan P; Fletcher GJ; Radhakrishnan M; Sivakumar J; Premkumar PS; Goel A; Zachariah UG; Abraham P
Indian J Med Microbiol; 2016; 34(3):335-41. PubMed ID: 27514956
[TBL] [Abstract][Full Text] [Related]
39. Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
Khan AJ; Saraswat VA; Ranjan P; Parmar D; Negi TS; Mohindra S
J Med Virol; 2019 Apr; 91(4):659-667. PubMed ID: 30431653
[TBL] [Abstract][Full Text] [Related]
40. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.
Eslam M; Leung R; Romero-Gomez M; Mangia A; Irving WL; Sheridan D; Spengler U; Mollison L; Cheng W; Bugianesi E; McLeod D; Zaitoun AM; Attino V; Goeltz D; Nattermann J; Douglas M; Booth DR; George J; Ahlenstiel G
J Hepatol; 2014 Aug; 61(2):235-41. PubMed ID: 24768758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
